VANCOUVER, BC — (GLOBE NEWSWIRE) — Derm-Biome Pharmaceuticals, Inc, a Vancouver based biopharmaceutical company focused on skin health, is pleased to announce that in a preclinical trial run by the… Read More
QULIPTA is the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) specifically developed for the preventive treatment of episodic migraine. AbbVie is the only pharmaceutical company to… Read More
Patents filed for novel small molecule SARS-CoV-2 Main Protease (Mpro) inhibitors VANCOUVER, BC — Variational AI, developer of the Enki™ generative artificial intelligence (AI) drug discovery platform to redefine the economics… Read More
VANCOUVER, BC — /CNW/ — A Vancouver-based therapeutics company has received regulatory approval to begin the second Phase II trial of its novel long lasting non-opioid pain medication. Sustained Therapeutics is… Read More
EP4R antagonist is Domain Therapeutics’ first fully-owned immuno-oncology asset to enter clinic Unique clinical strategy focused on unlocking new possibilities in the treatment of cancer STRASBOURG, FR – MONTREAL, CA —… Read More
